Literature DB >> 26113297

Hepatic TLR4 signaling in obese NAFLD.

Torfay Sharifnia1, Joseph Antoun2, Thomas G C Verriere1, Giovanni Suarez1, Julia Wattacheril1, Keith T Wilson3, Richard M Peek1, Naji N Abumrad2, Charles R Flynn4.   

Abstract

Nonalcoholic fatty liver disease occurs frequently in the setting of metabolic syndrome, but the factors leading to nonalcoholic steatohepatitis (NASH) are not fully understood. This study investigated Toll-like receptor 4 (TLR4) signaling in human liver with the goal of delineating whether activation of this pathway segregates those with nonalcoholic fatty liver from those with NASH. Experiments were performed using liver biopsy tissue obtained from class III obese subjects undergoing bariatric surgery, and extended to an immortalized human hepatocyte HepaRG cell line and primary human hepatocytes. The bacterial endotoxin lipopolysaccharide (LPS) and total free fatty acid levels were significantly increased in plasma of NASH patients. TLR4 mRNA levels were significantly increased in subjects with NASH compared with NAFL as was interferon regulatory factor (IRF) 3 in the myeloid differentiation factor 88-independent signaling pathway. In HepaRG cells, nuclear factor-κB (NF-κB) nuclear translocation and functional activity increased following treatment with the fatty acid, palmitate, and following exposure to LPS compared with hepatocytes stimulated with a lipogenic treatment that induced de novo lipogenesis. Palmitate and LPS induction of NF-κB activity was partially attenuated by chemical- or small-interfering RNA-mediated inhibition of TLR4. Expression of TLR4 and its downstream mediators was upregulated with palmitate and LPS. Similar results were observed using primary human hepatocytes from a lean donor. Interestingly, NF-κB activity assays showed obese donor hepatocytes were resistant to chemical TLR4 inhibition. In conclusion, TLR4 expression is upregulated in a large cohort of NASH patients, compared with those with NAFL, and this occurs within the setting of increased LPS and fatty acids.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  Toll-like receptor 4; lipopolysaccharide; nonalcoholic fatty liver; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; nuclear factor-κB; palmitate

Mesh:

Substances:

Year:  2015        PMID: 26113297      PMCID: PMC4537925          DOI: 10.1152/ajpgi.00304.2014

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  40 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

3.  Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4.

Authors:  G L Su; R D Klein; A Aminlari; H Y Zhang; L Steinstraesser; W H Alarcon; D G Remick; S C Wang
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

Review 4.  Gut-liver axis and sensing microbes.

Authors:  Gyongyi Szabo; Shashi Bala; Jan Petrasek; Arijeet Gattu
Journal:  Dig Dis       Date:  2011-04-27       Impact factor: 2.404

5.  A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation.

Authors:  Clett Erridge; Teresa Attina; Corinne M Spickett; David J Webb
Journal:  Am J Clin Nutr       Date:  2007-11       Impact factor: 7.045

6.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

Authors:  Kanji Yamaguchi; Liu Yang; Shannon McCall; Jiawen Huang; Xing Xian Yu; Sanjay K Pandey; Sanjay Bhanot; Brett P Monia; Yin-Xiong Li; Anna Mae Diehl
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

7.  Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

Authors:  Luca Miele; Venanzio Valenza; Giuseppe La Torre; Massimo Montalto; Giovanni Cammarota; Riccardo Ricci; Roberta Mascianà; Alessandra Forgione; Maria L Gabrieli; Germano Perotti; Fabio M Vecchio; Gianlodovico Rapaccini; Giovanni Gasbarrini; Chris P Day; Antonio Grieco
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

8.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

9.  Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.

Authors:  Sabine Thuy; Ruth Ladurner; Valentina Volynets; Silvia Wagner; Stefan Strahl; Alfred Königsrainer; Klaus-Peter Maier; Stephan C Bischoff; Ina Bergheim
Journal:  J Nutr       Date:  2008-08       Impact factor: 4.798

10.  Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation.

Authors:  Nyingi Kemmer; Guy W Neff; Edson Franco; Hussein Osman-Mohammed; John Leone; Erin Parkinson; Elizabeth Cece; Angel Alsina
Journal:  Transplantation       Date:  2013-11-27       Impact factor: 4.939

View more
  69 in total

1.  Ameliorative effects of glycine in an experimental nonalcoholic steatohepatitis and its correlation between TREM-1 and TREM-2.

Authors:  Zhang-Feng Dou; Ya-Rong Guo; Jin-Chun Liu; Ning Li; Bao Chai; Xiu-Qing Li; Rong Fu; Xiao-Juan Wang
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

2.  Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.

Authors:  Maria E Moreno-Fernandez; Daniel A Giles; Traci E Stankiewicz; Rachel Sheridan; Rebekah Karns; Monica Cappelletti; Kristin Lampe; Rajib Mukherjee; Christian Sina; Anthony Sallese; James P Bridges; Simon P Hogan; Bruce J Aronow; Kasper Hoebe; Senad Divanovic
Journal:  JCI Insight       Date:  2018-03-22

3.  Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4.

Authors:  Guang-Nian Zhao; Peng Zhang; Jun Gong; Xiao-Jing Zhang; Pi-Xiao Wang; Miao Yin; Zhou Jiang; Li-Jun Shen; Yan-Xiao Ji; Jingjing Tong; Yutao Wang; Qiao-Fang Wei; Yong Wang; Xue-Yong Zhu; Xin Zhang; Jing Fang; Qingguo Xie; Zhi-Gang She; Zhihua Wang; Zan Huang; Hongliang Li
Journal:  Nat Med       Date:  2017-05-08       Impact factor: 53.440

4.  Toll-like receptor 4 is critical for the development of resection-associated hepatic steatosis.

Authors:  Lauren K Barron; James W Bao; Bola G Aladegbami; Jason J Colasanti; Jun Guo; Christopher R Erwin; Brad W Warner
Journal:  J Pediatr Surg       Date:  2017-03-16       Impact factor: 2.545

Review 5.  Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?

Authors:  Tien S Dong; Jonathan P Jacobs
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-14

6.  Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome.

Authors:  Magar Ghazarian; Xavier S Revelo; Mark K Nøhr; Helen Luck; Kejing Zeng; Helena Lei; Sue Tsai; Stephanie A Schroer; Yoo Jin Park; Melissa Hui Yen Chng; Lei Shen; June Ann D'Angelo; Peter Horton; William C Chapman; Diane Brockmeier; Minna Woo; Edgar G Engleman; Oyedele Adeyi; Naoto Hirano; Tianru Jin; Adam J Gehring; Shawn Winer; Daniel A Winer
Journal:  Sci Immunol       Date:  2017-04-21

Review 7.  Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.

Authors:  Sena Bluemel; Brandon Williams; Rob Knight; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-29       Impact factor: 4.052

Review 8.  Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?

Authors:  Hiroshi Fukui
Journal:  Inflamm Intest Dis       Date:  2016-07-20

9.  Prevention of non-alcoholic steatohepatitis by long-term exercise via the induction of phenotypic changes in Kupffer cells of hyperphagic obese mice.

Authors:  Ikuru Miura; Shoichi Komine; Kosuke Okada; Shota Wada; Eiji Warabi; Fumihiko Uchida; Sechang Oh; Hideo Suzuki; Yuji Mizokami; Junichi Shoda
Journal:  Physiol Rep       Date:  2021-05

Review 10.  Gut microbiota and systemic immunity in health and disease.

Authors:  Bernard C Lo; Grace Y Chen; Gabriel Núñez; Roberta Caruso
Journal:  Int Immunol       Date:  2021-03-31       Impact factor: 4.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.